HighTower Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

HighTower Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-200	Closed	-$350	–	3836
2024 Q3	$350	Buy	+200	New	+$16.7K	﹤0.01%	3697
2022 Q3	–	Sell	-400	Closed	-$4K	–	3174
2022 Q2	$4K	Buy	+400	New	+$31.8K	﹤0.01%	3132
2020 Q2	–	Sell	-500	Closed	-$2K	–	2437
2020 Q1	$2K	Hold	500	–	–	﹤0.01%	2167
2019 Q4	$3K	Buy	+500	New	+$37.8K	﹤0.01%	2237

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HighTower Advisors's BMRN Position: Q2 2026 in Review

HighTower Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.4% in Q2 2026, selling an estimated $218K and leaving 43,302 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

HighTower Advisors first reported a position in BMRN in Q4 2013 and has held it in 40 quarters since. The position peaked at $3.24M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

HighTower Advisors held 43,302 shares of BioMarin Pharmaceuticals worth $2.48M as of Q2 2026.
HighTower Advisors sold 3,974 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $218K.
BioMarin Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1635 holding.
HighTower Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 40 quarters since.
HighTower Advisors's BioMarin Pharmaceuticals position peaked at $3.24M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.